Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Safety and Tolerability of Immunotherapy in Endometrial Cancer (5 minutes)

Experts discuss their experiences managing toxicities from immunotherapy agents
Ana Oaknin, MD, PhD
Program Director
Domenica Lorusso, MD, PhD
person default
Mansoor Raza Mirza, MD
Released: January 4, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.

Information on this Educational Activity

Program Director

Ana Oaknin, MD, PhD

Gynaecologic Cancer Programme
Vall d'Hebron Institute of Oncology (VHIO)
Hospital Universitari Vall d'Hebron
Vall d'Hebron Barcelona Hospital Campus
Barcelona, Spain

Ana Oaknin, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Clovis Oncology, Genmab, Immungen, PharmMar, Roche, and Tesaro.

Faculty

Domenica Lorusso, MD, PhD

Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.
Mansoor Raza Mirza, MD

Medical Director
Department of Oncology
Chief Oncologist
The Finsen Centre
Rigshospitalet
Copenhagen University Hospital
Copenhagen, Denmark

Mansoor Raza Mirza, MD, had disclosed that he has received consulting fees from AstraZeneca, GlaxoSmithKline, Merck, and Roche and fees for non-CME/CE services from AstraZenca, GlaxoSmithKline, and Roche.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Target Audience

This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with endometrial cancer.

Goal

The goal of this activity is to improve the knowledge of global learners to apply practice-changing clinical data and expert recommendations to optimize the care of patients with endometrial cancer.

Program Medium

This program has been made available online.

Related Content

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for HCC and BTCs

R. Kate Kelley, MD Amit G. Singal, MD, MS Released: January 27, 2021

From Clinical Care Options, download slides reviewing the integration of CAR T-cell therapy into community care

Michael R. Bishop, MD Jae H. Park, MD Released: January 26, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy into community care

Michael R. Bishop, MD Jae H. Park, MD Released: January 26, 2021

Brief expert slideset from Clinical Care Options (CCO) on how and when to test for NTRK fusions in patients with head and neck cancer

Aarti Bhatia, MD, MPH Released: January 5, 2021

Video Chapters


Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue